Two oral drugs for weight loss are now at U.S. pharmacies. The FDA approved oral semaglutide — the first oral GLP-1 for obesity — in December 2025. In April 2026, it approved orforglipron, sold as Foundayo by Eli Lilly, the first oral small-molecule GLP-1. A third candidate, aleniglipron, posted Phase 2b results in Nature Medicine: up to 12.1% body-weight loss over 36 weeks, in a trial led by Dr. Robert Kushner, professor emeritus of medicine at Northwestern University Feinberg School of Medicine. The WHO issued its first formal obesity treatment guideline in December 2025, backing GLP-1s for a chronic, relapsing disease. About 170,000 Americans had already started on oral pills by March 2026. The drugs work the same way as injectable Wegovy and Ozempic — they mimic a hormone that suppresses appetite — but you swallow them.

1. Oral Pills Change Who Gets Help (Obesity Medicine Specialists, Including Drs. Jaisinghani and Kushner)

Millions skipped treatment because of the needle. Pills bring them back.

Many patients skipped treatment because of the injection, not the diagnosis. Dr. Priya Jaisinghani, a clinical assistant professor at NYU Grossman School of Medicine and endocrinologist at NYU Langone Medical Associates, says pills could reach patients who were eligible for GLP-1s for years but didn't start. "Having an oral formulation, it may lower the psychological barrier that patients have to starting treatment," she told the AAMC. GLP-1 injections were already proven to work — a real portion of patients who qualified just never started them.

These pills pair with other medications more easily than injections do. Dr. Kushner, who led the aleniglipron trial, notes that small-molecule drugs like orforglipron and aleniglipron don't interfere with other medications the way peptide-based injectables sometimes can. They could also cost less to produce at scale. The WHO backed this framing in December 2025 with its first global obesity guideline, calling the condition a chronic disease requiring long-term medical management.

2. But the Safety Picture Still Has Gaps (Safety Skeptics, Including Drs. Dushay and Sahyouni)

Long-term data doesn't exist yet, and misuse is already in the numbers.

Nobody knows what happens to patients after three years on these pills. Dr. Jody Dushay, an assistant professor of medicine at Harvard Medical School and endocrinologist at Beth Israel Deaconess Medical Center in Boston, worries that pills make it too easy to start without clinical oversight. "If something seems too good to be true, often that plays out in some way," she told the AAMC. She flags eating disorder risk and inappropriate prescribing — problems that are harder to spot when patients don't come in regularly.

GLP-1 overdose calls have risen nearly 1,500% since 2019. Dr. Jamal Sahyouni, a diabetologist at Clinch Valley Medical Center, has seen this firsthand: "People just overdoing it to lose weight more than supposed to. That's where you cross in line with the problem." Dr. Chun-Su Yuan, a professor at the University of Chicago Pritzker School of Medicine, adds a concern specific to pills: oral forms are far easier to counterfeit than injectables. And in a large semaglutide safety trial, patients aged 75 and older had fracture rates four times higher than the placebo group.

3. And Most People Who Need One Still Can't Get One (Access Advocates, Including Moises Arjona Jr.)

The coverage gaps didn't close when the pills arrived.

The price dropped, but the coverage problem didn't. The Trump administration negotiated GLP-1 costs down to around $245 a month for some Medicare and Medicaid patients in 2025 — less than half the prior price for injections. But only 12 state Medicaid programs now cover GLP-1s for obesity, down from 16 in 2025, with Massachusetts ending coverage on July 1. A Medicare GLP-1 Bridge Program launched in July 2026, but it covers only some Part D beneficiaries. KFF polling found 56% of current GLP-1 users still say these drugs are difficult to afford. The CBO estimated that broad Medicare coverage would add $35.5 billion in federal spending from 2026 to 2034.

Stopping GLP-1s without lifestyle changes means the weight comes back. Moises Arjona Jr., CEO of Unidos Contra la Diabetes and a 2026 Healthy Communities Fellow, argues the medication is running ahead of the support patients actually need. "They are not a silver bullet," he wrote. "These drugs are not cures; they are supports." Patients who stop GLP-1s without lifestyle changes typically regain most of the lost weight within 18 months.

Where This Lands

Obesity medicine specialists say oral pills could finally reach the millions who skipped treatment to avoid injections — and they have the WHO and the clinical data behind them. Safety skeptics think the misuse numbers already showing up are a real warning: we moved fast and the long-term safety data still doesn't exist. The access critics' numbers are hard to dismiss: more than half of current GLP-1 users say they can't afford the drugs, and most people who could benefit still can't get coverage. All three camps agree the drugs work. They disagree on safety timelines, who pays, and whether a pill is enough on its own.

Sources